The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
In a Phase 2b study with pegylated interferon and ribavirin, Pharmasset's PSI-7977 had a 100 percent success rate against Hepatitis C genotypes 2 and 3.
Continue reading »Hoping to simplify and improve Hepatitis C treatment, Achillion is testing several proprietary compounds - including the recent start of a Phase 1 trial to assess ACH-2684.
Continue reading »Focusing on an all-oral treatment, Pharmasset and Tibotec are working together to simplify and improve Hepatitis C treatment.
Continue reading »Striving to create a preventative Hepatitis C vaccine, a European project will focus on nanogels.
Continue reading »Boasting several benefits over the currently approved Hepatitis C drugs, Medivir's TMC435 has been granted fast track status by the FDA. Additionally, TMC435 will partake in a new trial to assess its validity within an interferon-free regimen.
Continue reading »Compared to what had been the standard treatment for around 20 years, triple therapy with Incivek can eliminate Hepatitis C in a much greater percentage of people in about half the time.
Continue reading »In addition to receiving fast track status from the FDA, setrobuvir has been granted a U.S. patent. Currently in a Phase IIb study, data on setrobuvir's efficacy against Hepatitis C is expected in the latter part of 2011.
Continue reading »When added to pegylated interferon and ribavirin therapy, Medivir's Hepatitis C protease inhibitor TMC435 was highly safe and effective, a dramatic improvement over the standard treatment in chronic Hepatitis C genotype 1 treatment-experienced individuals.
Continue reading »Because it will more than double the current cost of treatment, the Fair Pricing Coalition is furious about the price affixed to Incivek™, the newest approved Hepatitis C medication.
Continue reading »With the approval of Incivek™ (telaprevir) for the treatment of those with Hepatitis C, genotype 1, and the potential to cut treatment time to just 24 weeks, many questions arise. Here we have summarized some of these questions.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
